secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001821586-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake reports Q1 2025 cash of $480.1M, secures up to $500M debt facility; Phase 3 HS enrollment complete
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.
- Up to $500M non-dilutive debt facility with Hercules Capital; $75M drawn at close, extends cash runway into 2028.
- Phase 3 VELA program in hidradenitis suppurativa fully enrolled; top-line results expected around September 2025.
- R&D expenses $36.5M (similar to prior quarter); G&A expenses $11.0M (up from $9.2M).
- Interim readout of Phase 2 LEDA trial in palmoplantar pustulosis presented; primary endpoint readout expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/0001821586-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/mnlk-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001821586-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer